en

Sign up
Investments involve risks and are not suitable for all investors.

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

Home・Stock List・CRISPR Therapeutics AG
Search

CRISPR Therapeutics AG

Open

Sector Healthcare

50.59 0.26

Buy

Price update 4 Nov 2024, 20:54 UTC

BuySell

Overview

Share price change

24h

Current

Min

49.09

Max

51.82

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+38.55 upside

Dividends

By Dow Jones

Next Earnings

8 Nov 2024

News Sentiment

By Acuity

54%

46%

305 / 390 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bullish Evidence

48.04 / N/A Support & Resistance

CRISPR Therapeutics AG Chart

Past performance is not a reliable indicator of future results.

Related News

8 Dec 2023, 20:56 UTC

Major Market Movers

Bluebird Bio Shares Slide 41% on Black-Box Label, Higher Price for Sickle-Cell Treatment

DJ

Read

26 Sept 2024, 16:08 UTC

Earnings
Acquisitions, Mergers, Takeovers

Pfizer's Strategy Looks Shakier After Sickle-Cell Disappointment -- Barrons.com

DJ

Read

26 Sept 2024, 14:20 UTC

Acquisitions, Mergers, Takeovers

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. -- IBD

DJ

Read

11 Apr 2024, 14:46 UTC

Acquisitions, Mergers, Takeovers

Vertex Pharmaceuticals Seeks a Second Act With $4.9B Deal to Buy Alpine Immune -- Barrons.com

DJ

Read

8 Dec 2023, 18:45 UTC

Top News

FDA Approves World's First Crispr Gene-Editing Drug for Sickle-Cell Disease -- 2nd Update

DJ

Read

8 Dec 2023, 16:45 UTC

Top News

FDA Approves World's First Crispr Gene-Editing Drug for Sickle-Cell Disease -- Update

DJ

Read

8 Dec 2023, 16:21 UTC

Top News

FDA Approves World's First Crispr Gene-Editing Drug for Sickle-Cell Disease -- WSJ

DJ

Read

24 Nov 2023, 12:00 UTC

Top News

Gene Editing Will Change Medicine -- and Maybe Health Investing Too -- Heard on the Street -- WSJ

DJ

Read

Peer Comparison

Price change

CRISPR Therapeutics AG Forecast

Price Target

By TipRanks

38.55% upside

12 Months Forecast

Average 70.33 USD  38.55%

High 105 USD

Low 30 USD

Based on 17 Wall Street analysts offering 12 month price targets forCRISPR Therapeutics AG - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

17 ratings

9

Buy

6

Hold

2

Sell

Based on 17 analysts giving stock ratings to CRISPR Therapeutics AG - Dist in the past 3 months.

Technical Score

By Trading Central

48.04 / N/ASupport & Resistance

Short Term

Very Strong Bullish Evidence

Recent bullish events outweigh bearish events.

Intermediate Term

Bullish Evidence

Recent bullish events outweigh bearish events.

Long Term

Bearish Evidence

All events are bearish.

Sentiment

By Acuity

305 / 390 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

$

Other stocks from the sector

LLY

Eli Lilly and Co.

805.71

↓-1.45%

UNH

UnitedHealth Group Inc

556.95

↓-1.68%

JNJ

Johnson and Johnson

158.12

↓-1.16%

NVO

Novo Nordisk A-S

109.92

↓-1.81%

ABBV

AbbVie Inc

200.71

↓-1.24%